MedTrace Logo

A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata

NCT04445363 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2024-03-06

No results posted yet for this study

Summary

This study includes a dose escalation part(phase I) and a dose extension part(phase II).

Conditions

  • Alopecia Areata(AA)

Interventions

DRUG

Jaktinib hydrochloride cream

Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks

DRUG

Placebo

Dose extension: Placebo

Sponsors & Collaborators

  • Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • qianjin lu, M.D. · the Second Xiangya Hospital, Central South University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-12
Primary Completion
2024-12-01
Completion
2024-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04445363 on ClinicalTrials.gov